Otsuka Pharmaceutical Co., the Japan-based company, announced on Friday that its late-stage trial for treating kidney disease showed an over 50% reduction in protein in patients’ urine. The drug, 4578, was tested on patients with a specific type of kidney disease and yielded promising results, demonstrating significant improvement in reducing proteinuria, a common indicator of kidney damage.
Source: https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3S90R8:0-otsuka-s-kidney-disease-drug-shows-over-50-reduction-in-protein-in-urine